Linch David C, Hills Robert K, Burnett Alan K, Russell Nigel, Gale Rosemary E
Department of Haematology, University College London (UCL) Cancer Institute, London, UK.
Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Br J Haematol. 2022 Mar;196(6):1348-1352. doi: 10.1111/bjh.17981. Epub 2021 Dec 6.
Although we earlier reported a very poor outcome for younger adult patients with isocitrate dehydrogenase 2 (IDH2) -mutated acute myeloid leukaemia (AML) entered into UK trials compared to IDH2 and IDH2 -mutated patients, this was not corroborated by a study from the German-Austrian AML Study Group. We have therefore investigated a later cohort of IDH2-mutated patients to identify any changes in outcome and whether this could inform the optimal treatment for IDH2 AML. We found an improved outcome for IDH2 -mutated AML in the later trials and the data suggests that this may be due to the increased use of allogeneic transplantation to consolidate first remission.
尽管我们之前报告称，与异柠檬酸脱氢酶2（IDH2）野生型急性髓系白血病（AML）患者相比，参加英国试验的IDH2突变型年轻成年AML患者预后非常差，但德国-奥地利AML研究组的一项研究并未证实这一点。因此，我们对一组较晚的IDH2突变患者进行了调查，以确定预后是否有任何变化，以及这是否能为IDH2 AML的最佳治疗提供依据。我们发现，在后来的试验中，IDH2突变型AML的预后有所改善，数据表明，这可能是由于强化首次缓解时增加了异基因移植的使用。
